Research
Research Alert: Abt Q1 In Line With Expectations Amid Nutrition Headwinds
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Abbott delivered Q1 2026 results aligned with expectations, reporting adjusted EPS of $1.15 (+6% Y/Y) matching consensus and total sales of $11.164B (+7.8% Y/Y reported, +3.7% comparable). The successful completion of the Exact Sciences acquisition on March 23 established Abbott as a leader in oncology diagnostics, in our view, contributing $96M in Cancer Diagnostics sales (+13.4% Y/Y comparable). Abbott updated full-year 2026 guidance projecting comparable sales growth of 6.5%-7.5% Y/Y (unchanged) and adjusted EPS of $5.38-$5.58, including $0.20 dilution from the deal. Medical Devices continued strong performance with $5.54B in sales (+13.2% Y/Y), while Diabetes Care maintained positioning at $2.080B (+7.4% Y/Y comparable). However, Nutrition faced headwinds with sales declining to $2.017B (-7.7% Y/Y comparable), particularly in U.S. pediatric business. We believe the EXAS integration positions Abbott well in the ~$60B U.S. cancer screening market, though Nutrition segment recovery remains key to monitor.
$ABT